Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 10 min ago
Peer-reviewedCC BY-NC-NDJournal of gastrointestinal oncology

Clinical applications and recent advances in multimodal image fusion for hepatocellular carcinoma diagnosis: a narrative review.

4 affiliations
  1. 1Department of Nephrology, The First Hospital of Anhui University of Science and Technology, Huainan, China.
  2. 2School of Computer Science and Engineering, Anhui University of Science & Technology, Huainan, China.
  3. 3School of Medicine, Anhui University of Science & Technology, Huainan, China.
  4. 4Anhui Provincial Academician Workstation of Anhui University of Science & Technology for Autoimmune Disease Diagnostic Technology, Huainan, China.

Abstract

Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality worldwide, and patient outcomes depend strongly on early detection, accurate staging, and timely treatment planning. However, single-modality imaging cannot fully characterize tumor heterogeneity because each modality provides only partial anatomical, functional, or metabolic information. Multimodal image fusion (MIF) addresses this limitation by integrating complementary data from ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). This narrative review summarizes advances in MIF and its clinical applications in HCC. A targeted literature search of relevant databases was conducted, with a focus on recent and key English-language publications. The search strategy included terms related to "hepatocellular carcinoma", "CT", "MRI", "PET", "image registration", "image-guided ablation", and "artificial intelligence". This review summarizes commonly used image-fusion strategies and recent advances in their clinical applications for HCC, including lesion detection, staging, ablation guidance, and post-treatment assessment. It also discusses the emerging role of artificial intelligence (AI) in image registration, fusion, and interpretation. MIF has shown clear clinical promise in supporting precision diagnosis and personalized management of HCC. Although MIF has shown clear clinical promise, its broader adoption remains limited by technical interoperability, cost, workflow complexity, and the need for standardized training. Future progress in system integration, algorithm robustness, and multidisciplinary collaboration may further expand its value in precision diagnosis and personalized management of HCC.

Related

  1. Multimodal AI in Hepatocellular Carcinoma: Bridging Diagnosis, Therapy and Prognosis Toward Precision Oncology.
    Xinyi Chen, Fazhao Li, Yan Xu +3
    Journal of hepatocellular carcinomaPeer-reviewedCC BY-NCFull textMedical imaging & radiologyEurope PMC
  2. Current imaging methods and molecular biomarkers for hepatocellular carcinoma diagnosis: a narrative review.
    Almadodi Reema Mohammed Salem, Habiba Alaaeldin Mohmed Elhussieni Seada, Yuan Seng Wu +8
    Journal of gastrointestinal oncologyPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  3. Missed Diagnosis in Alcohol‐Related Hepatocellular Carcinoma: A Call for Alcohol Consumption and Liver Disease Early Detection
    Victoria Mignot, Aurore Baron, Thomas Decaens +1
    Liver international : official journal of the International Association for the Study of the LiverPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Adherencia a la vigilancia del carcinoma hepatocelular y su asociación con el estadio tumoral al diagnóstico: experiencia de un hospital universitario Adherence to Hepatocellular Carcinoma Surveillance and Its Association with Tumor Stage at Diagnosis: Experience at a University Hospital
    Gabriel Adrián Mariño Camacho, Jonathan David Salmon Pico, Lorena Bortot +5
    Acta gastroenterologica LatinoamericanaPeer-reviewedCC BY-NC-SAFull textGeneral medicineEurope PMC
  5. From recognition to delivery: nucleic acid aptamers in miRNA-related diagnosis and therapy of hepatocellular carcinoma
    Shihao Du, Shaokang Wu, Ruomiao Li +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyFrontiersCrossrefDOAJ
BibTeX
@article{gan2026clinical,
  title = {{Clinical applications and recent advances in multimodal image fusion for hepatocellular carcinoma diagnosis: a narrative review.}},
  author = {Zhirui Gan and Xuejia Zheng and Feng Zhu and Liu Xiang and Jiawen Feng and Yong Dai},
  journal = {Journal of gastrointestinal oncology},
  year = {2026},
  month = aug,
  doi = {10.21037/jgo-2026-0697},
  url = {https://europepmc.org/article/MED/42996887},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Clinical applications and recent advances in multimodal image fusion for hepatocellular carcinoma diagnosis: a narrative review.
AU  - Zhirui Gan
AU  - Xuejia Zheng
AU  - Feng Zhu
AU  - Liu Xiang
AU  - Jiawen Feng
AU  - Yong Dai
PY  - 2026
DA  - 2026/08/18
JO  - Journal of gastrointestinal oncology
DO  - 10.21037/jgo-2026-0697
UR  - https://europepmc.org/article/MED/42996887
AB  - Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality worldwide, and patient outcomes depend strongly on early detection, accurate staging, and timely treatment planning. However, single-modality imaging cannot fully characterize tumor heterogeneity because each modality provides only partial anatomical, functional, or metabolic information. Multimodal image fusion (MIF) addresses this limitation by integrating complementary data from ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). This narrative review summarizes advances in MIF and its clinical applications in HCC. A targeted literature search of relevant databases was conducted, with a focus on recent and key English-language publications. The search strategy included terms related to "hepatocellular carcinoma", "CT", "MRI", "PET", "image registration", "image-guided ablation", and "artificial intelligence". This review summarizes commonly used image-fusion strategies and recent advances in their clinical applications for HCC, including lesion detection, staging, ablation guidance, and post-treatment assessment. It also discusses the emerging role of artificial intelligence (AI) in image registration, fusion, and interpretation. MIF has shown clear clinical promise in supporting precision diagnosis and personalized management of HCC. Although MIF has shown clear clinical promise, its broader adoption remains limited by technical interoperability, cost, workflow complexity, and the need for standardized training. Future progress in system integration, algorithm robustness, and multidisciplinary collaboration may further expand its value in precision diagnosis and personalized management of HCC.
SN  - 2078-6891
SN  - 2219-679X
ER  -